BOSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Rezera Inc. (the 'Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, today announced that the recently completed RESOLVE-1 Phase 2 trial evaluating ruvonoflast in participants with elevated cardiometabolic risk has been accepted as a late-breaking Featured Science presentation at the American H...

Provides 119 Buses to Charter Thousands of Attendees